Atrial fibrillation (AF) is a common cardiac arrhythmia and it is associated with systemic
thromboembolism. Until recently, vitamin K antagonists (VKA) such as warfarin were the only …

Non-vitamin K antagonist oral anticoagulants (NOACs)–dabigatran, rivaroxaban, apixaban
and edoxaban–are well established in terms of preventing stroke or systemic embolism in …

Background Warfarin is commonly used as a secondary prevention of stroke in patients with
atrial fibrillation (AF). However, limitations have been observed even with the use of this …

Atrial fibrillation (AF) is a major cause of ischaemic stroke. The majority of these strokes can
be prevented by treatment with oral anticoagulation therapy. The advent of non-vitamin K …

Real-world data are a well-recognized component within the drug lifecycle, and such data
are generated from a range of sources and study designs, including claims databases …

Aims Observational studies have investigated the effectiveness and safety of direct oral
anticoagulants (DOACs) and vitamin K antagonists (VKAs) used in nonvalvular atrial …

Background Comparative data of non‐vitamin K antagonist oral anticoagulants (NOAC) are
lacking in patients with atrial fibrillation (AF). Objective We compared effectiveness and …

Worldwide there is a tremendous need for affordable anticoagulants that do not require
monitoring. The advent of the non-warfarin oral anticoagulant drugs represents a major …

Recently, novel oral anticoagulants (NOACs) have been approved for stroke prevention in
patients with atrial fibrillation (AF). Although these agents overcome some disadvantages of …

Aim: To compare real-world effectiveness/safety of non-vitamin K antagonist oral
anticoagulants and vitamin K antagonists among patients with non-valvular atrial fibrillation …